51st week of 2012 patent applcation highlights part 51 |
Patent application number | Title | Published |
20120322697 | COMPOSITIONS AND METHODS FOR ENHANCING FLUID RECOVERY FOR HYDRAULIC FRACTURING TREATMENTS - A method of altering the wettability of a subterranean formation comprising the steps of providing a fluid with a FEA; introducing the fluid into a subterranean formation whereby the wettability of the formation is altered, wherein the FEA is selected from a group consisting of organosiloxane, organosilane, fluoro-organosiloxane, fluoro-organosilane, and fluorocarbon compounds. | 2012-12-20 |
20120322698 | TREATMENT FLUIDS COMPRISING PUMICITE AND METHODS OF USING SUCH FLUIDS IN SUBTERRANEAN FORMATIONS - Methods and compositions for the treatment of subterranean formations, and more specifically, treatment fluids containing pumicite and methods of using these treatment fluids in subterranean formations, are provided. An example of a method is a method of displacing a fluid in a well bore. Another example of a method is a method of separating fluids in a well bore in a subterranean formation. An example of a composition is a spacer fluid comprising pumicite and a base fluid. | 2012-12-20 |
20120322699 | Method of Preventing Scale Formation During Enhanced Oil Recovery - A method for preventing scale formation during an alkaline hydrocarbon recovery process is disclosed. An aqueous solution (e.g., recovered sea water, water produced from the subterranean reservoir, or a combination thereof) having a concentration of metal cations (e.g., calcium, magnesium) is provided. A stoichiometric amount of an organic complexing agent relative to the concentration of metal cations is introduced into the aqueous solution such that the organic complexing agent forms aqueous soluble cation-ligand complexes with the metal cations. At least one alkaline is introduced into the aqueous solution to form an injection fluid having a pH value of at least 10. The cation-ligand complexes remain soluble in the injection fluid such that scale formation is prevented when the injection fluid is injected into a subterranean reservoir. | 2012-12-20 |
20120322700 | Nano-Sized Particles for Stabilizing Viscoelastic Surfactant Fluids - An aqueous, viscoelastic fluid gelled with a viscoelastic surfactant (VES) is stabilized and improved with an effective amount of an alkaline earth metal oxide alkaline earth metal hydroxide, alkali metal oxides, alkali metal hydroxides transition metal oxides, transition metal hydroxides, post-transition metal oxides, and post-transition metal hydroxides. These fluids are more stable and have a reduced or no tendency to precipitate, particularly at elevated temperatures. The additives may reduce the amount of VES required to maintain a given viscosity. These stabilized, enhanced, aqueous viscoelastic fluids may be used as treatment fluids for subterranean hydrocarbon formations, such as in hydraulic fracturing. The particle size of the magnesium oxide or other agent may be nanometer scale, which scale may provide unique particle charges that use chemisorption, crosslinking and/or other chemistries to associate and stabilize the VES fluids. | 2012-12-20 |
20120322701 | LOW VISCOSITY MARINE CYLINDER LUBRICATING OIL COMPOSITIONS - Disclosed herein are marine cylinder lubricants which comprise a major amount of basestock selected from the group consisting of a Group II basestock, a Group III basestock and mixtures thereof, wherein the marine cylinder lubricant has a kinematic viscosity at 100° C. of from 13 to about 16.2 cSt; and contains less than about 10 wt. % bright stock. Also disclosed are marine cylinder lubricants which comprise a major amount of basestock selected from the group consisting of a Group II basestock, a Group III basestock and mixtures thereof, wherein the marine cylinder lubricant has a kinematic viscosity at 100° C. of between about 13 and about 16.2 cSt; and a total base number of 5 to about 70, and further wherein the marine cylinder lubricant contains less than about 10 wt. % bright stock. | 2012-12-20 |
20120322702 | LUBRICATING COMPOSITION CONTAINING MULTIFUNCTIONAL BORATED HYDROXYLATED AMINE SALT OF A HINDERED PHENOLIC ACID - Multi-functional additives which impart improved antioxidancy to lubricating oil compositions and frictional properties resulting in improved fuel economy in an internal combustion engine are disclosed. More particularly disclosed is a boron containing salt of an oil soluble hydroxylated amine and a hindered phenolic acid product prepared by: a) reacting an oil soluble hydroxylated amine of the general formula II: | 2012-12-20 |
20120322703 | COMPOSITIONS HAVING REDUCED FRICTIONAL COEFFICIENT, METHOD OF MANUFACTURE THEREOF AND ARTICLES COMPRISING THE SAME - Disclosed herein is a composition comprising an organic polymer and about 2 to about 10 weight percent of an ionic liquid. The ionic liquid can be a halogenated or non-halogenated ionic liquid. Disclosed herein too are articles manufactured from the composition. | 2012-12-20 |
20120322704 | LUBRICANT COMPOSITION - A lubricating oil composition of the invention contains: (a) a base oil for a lubricating oil having a kinematic viscosity at 100 degrees C. in a range of 2 mm | 2012-12-20 |
20120322705 | LUBRICANT FORMULATION WITH HIGH OXIDATION PERFORMANCE - A Group IV/Group V lubricating composition providing improved antioxidation performance comprises from 5 wt. % to 40 wt. % of a Group V base oil component, such as alkylated naphthalene, at least 30 wt. % of a Group IV base oil component, such as one or more polyalphaolefin base stocks, and from 0.25 wt. % to 1.5 wt. % of a trithiophosphate-containing compound. The trithiophosphate-containing compound is preferably C | 2012-12-20 |
20120322706 | LUBRICATING OIL COMPOSITION - The lubricating oil composition of the invention comprises a lubricant base oil, a 3,4,5-trihydroxybenzoic acid ester at 5-5000 ppm by mass, and a phosphorus compound at 0.001-10.0% by mass, based on the total mass of the lubricating oil composition. The lubricating oil composition of the invention significantly lowers wear and exhibits a stable low frictional coefficient, while having a high rust-preventing effect for iron-based sliding sections. The lubricating oil composition of the invention is therefore suitable for prolonged use, and exhibits a notable effect for energy savings as well due to its stable low frictional coefficient property. | 2012-12-20 |
20120322707 | GREASE COMPOSITIONS COMPRISING ESTOLIDE BASE OILS - Provided herein are grease compositions comprising at least one estolide compound of formula: | 2012-12-20 |
20120322708 | CONSUMER PRODUCTS - Compositions including bleach components and sensitive components providing a means for separating and therefore protecting sensitive components. The sensitive component is introduced via a protected particle including a substrate for an enzyme also present in the composition. | 2012-12-20 |
20120322709 | COMPOSITIONS COMPRISING AN EFFICIENT PERFUME BLOOM - The present invention provides personal care compositions having efficient perfume blooms or bursts. The personal care compositions include shampoo and body wash compositions, and comprise perfume materials having high perceived odor intensity at low concentrations of perfume materials. | 2012-12-20 |
20120322710 | POLY PHOSPHATE FUNCTIONALIZED ALKYL POLYGLUCOSIDES FOR ENHANCED FOOD SOIL REMOVAL - A cleaning composition including a primarily C | 2012-12-20 |
20120322711 | HIGH QUALITY BAR SOAP INCORPORATING TRICLINIC TALC - A personal cleansing composition includes soap at a concentration of at least 10 weight percent of the composition; and talc having a primarily triclinic crystal structure, the talc being included at a concentration of between 0.1 and 15 weight percent of the composition. A method for enhancing lathering properties of a bar soap includes the step of molding a bar soap from such a composition. | 2012-12-20 |
20120322712 | Stable Soap Based Cleansing System - Disclosed is a liquid soap composition which comprises:
| 2012-12-20 |
20120322713 | LIQUID DETERGENT COMPOSITION WITH ABRASIVE PARTICLES - The present invention relates to a dishwashing composition comprising abrasive particles and a suspending aid selected from the group consisting of crystalline wax structurants, micro-fibril-cellulose, amido-gellants, di-benzylidene polyol acetal derivatives, and mixtures thereof, and the process and use thereof. | 2012-12-20 |
20120322714 | BRANCHED POLYESTERS WITH SULFONATE GROUPS - Branched polyesters with sulfonate groups obtainable by the reaction of the components A, B, optionally C and optionally D to give branched polyesters, where the component A is selected from the group of α,β-olefinically unsaturated dicarboxylic acids, and the component B is selected from the group of tri- or higher-functional alcohols, the optional component C is selected from the group of difunctional alcohols or of difunctional carboxylic acids without α,β-olefinically unsaturated bonds, the optional component D is selected from fatty acids or fatty alcohols, and the subsequent reaction of the resulting branched polyesters with hydrogen sulfite, where the molar amount of hydrogen sulfite is at most 95 mol %, based on the amount of α,β-olefinically unsaturated dicarboxylic acid. | 2012-12-20 |
20120322715 | SERINE HYDROLASE FORMULATION - The storage stability of a serine hydrolase acting on ester bonds in a formulation without a protease can be improved by incorporating a serine protease inhibitor. | 2012-12-20 |
20120322716 | Fragrant gel polymer with water - The fragrant gel polymer system is a process where a fragrance formulation is divided and blended with a polymer and a cross-linking agent. The polymer is then liquefied and made homogenous with a solvent, including esters. The solvent modifies viscosity and later eases the mixing of the polymer with the cross-linking agent. The cross linking agent is then liquefied and blended with water and aliphatic alcohol reducing steric hindrance. Mixing of the fragrance carrying polymer and the cross linking agent results in a gel that sets in less time and with less syneresis than existing processes. The resulting gel achieves a near transparent form and receives dyes while attaining various molded shapes. | 2012-12-20 |
20120322717 | Compounds and assays for controlling Wnt activity - The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions. | 2012-12-20 |
20120322718 | Amygels in organic solvent for biomedical applications - A starch-based Amygel for the controlled delivery of a biologically active agent is described. The Amygel comprises a dispersed phase, and a dispersion medium consisting substantially of an organic solvent. The dispersed phase includes a polymeric network comprising a hydrolyzable polymeric substance derived from starch, and a cross-linker. In various embodiments, the polymeric starch-derived network includes amylose, amylopectin, soluble starch or a combination thereof. The cross-linker is a molecule having at least two carboxyl moieties. The hyrogel is biocompatible and biodegradable, and suitable for loading with biologically active agents including small molecule therapeutics, macromolecules such as proteins, polysaccharides and nucleic acids. Upon administration to a host animal, the Amygel biodegrades, releasing as degradation products only naturally-occurring sugar molecules that are non-toxic and non-immunogenic to the host. | 2012-12-20 |
20120322719 | METHODS OF TREATMENT OF FATTY LIVER DISEASE BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC PATHWAYS - A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis. | 2012-12-20 |
20120322720 | STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTILIZING SUCH VEHICLES - This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10 | 2012-12-20 |
20120322721 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER - The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts. | 2012-12-20 |
20120322722 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use - The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy. | 2012-12-20 |
20120322723 | USE OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FOR PREPARING MEDICAMENT FOR PREVENTING OR TREATING EPITHELIUM TRAUMA OF INTESTINAL MUCOSA - The invention provides a use of the interleukin-1 receptor antagonist protein for preparing a medicament for preventing or treating epithelium trauma of the intestinal mucosa, wherein the protein is selected from: (a) a protein having an amino acid sequence as shown in SEQ ID NO: 1; (b) a protein which has a sequence having at least 70% homology with the amino acid sequence in the (a) and has the effect of preventing or treating epithelium trauma of the intestinal mucosa. The invention also provides a pharmaceutical composition comprising the protein (a) or (b) as the active component. | 2012-12-20 |
20120322724 | MOLECULES FOR TARGETING COMPOUNDS TO VARIOUS SELECTED ORGANS OR TISSUES - The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat a pathology of the muscle or heart, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the muscle cells or heart cells. | 2012-12-20 |
20120322725 | GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY - Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided. | 2012-12-20 |
20120322726 | THERAPEUTIC AGENT FOR EATING DISORDERS - Disclosed is a highly safe and effective therapeutic agent for eating disorders, which contains, as an active ingredient, a water-soluble fraction of a hydrolysis product of casein. The hydrolysis product is obtained by means of pepsin. | 2012-12-20 |
20120322727 | Pharmaceutical Compositions for Intranasal Administration for the Treatment of Neurodegenerative Disorders - In one embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In another embodiment of the invention, a pharmaceutical composition for intranasal administration comprises clioquinol, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In yet another embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, clioquinol, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions of the invention may be used to treat or prevent a neurodegenerative disorder such as Alzheimer's disease, stroke, Parkinson's disease, multiple sclerosis, spinal cord injuries, and/or traumatic brain injuries and the like, in addition to other systemic and local diseases. | 2012-12-20 |
20120322728 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES - The present invention relates to thiazolidinedione analogues and pharmaceutical compositions that are useful for treating and/or preventing diabetes mellitis, optionally in combination with a second treatment. Furthermore, the present invention also provides methods of inducing remission of the symptoms of diabetes mellitis in a patient comprising administering a thiazolidinedione analogue and a GLP-1 agonist. | 2012-12-20 |
20120322729 | HIGH ACTIVITY GROWTH FACTOR MUTANTS - The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity. | 2012-12-20 |
20120322730 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ANEMIA - Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs. | 2012-12-20 |
20120322731 | NOVEL CYTOKINE CONTAINING COMPOSITIONS - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 2012-12-20 |
20120322732 | CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL) - A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease. | 2012-12-20 |
20120322733 | NOVEL PEPTIDYL ALPHA-HYDROXYGLYCINE ALPHA-AMIDATING LYASES - The present patent application concerns an enzyme capable of catalysing the conversion of a α-hydroxyglycine to an α-amide and the use of such enzymes for producing a C-terminal α-amidated peptide. | 2012-12-20 |
20120322734 | Pharmaceutical Compositions Including Low Dosages of Desmopressin - The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed. | 2012-12-20 |
20120322735 | MODIFIED GROWTH HORMONE POLYPEPTIDES - We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess. | 2012-12-20 |
20120322736 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN - The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia. | 2012-12-20 |
20120322737 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE - The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention. | 2012-12-20 |
20120322738 | CONJUGATED FVIII VARIANTS - The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof. | 2012-12-20 |
20120322739 | Albumin Variants - The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2012-12-20 |
20120322741 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2012-12-20 |
20120322742 | THERAPEUTICS TO INHIBIT MLL-MENIN INTERACTION FOR TREATING LEUKEMIA - Cell permeable peptides derived from MLL that block the interaction of MLL with menin for the treatment of acute myeloid and acute lymphoid leukemia are disclosed. Small molecules interfere with the interaction of MLL with any of its binding partners. | 2012-12-20 |
20120322743 | Compositions and Methods for Diagnosing and Treating Melanoma - Described herein are compositions and methods for the diagnosis, prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma, as well as various nucleic acid molecules relating thereto or derived therefrom. | 2012-12-20 |
20120322744 | POLY-PEGYLATED PROTEASE INHIBITORS - Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods. | 2012-12-20 |
20120322745 | OPTIMIZED METHOD FOR OBTAINING ACE ACTIVITY INHIBITORY PEPTIDES FROM WHEY, ACE INHIBITORY PEPTIDES AND FOOD COMPRISING THEM - An optimized method for obtaining ACE activity inhibitory peptides includes the steps of whey ultrafiltration for obtaining a whey concentrate, enzymatic hydrolysis, hydrolysate ultrafiltration and inhibitory peptide separation. The method includes selecting and adding a mixture having suitable proportion and amount of two microbial proteases and having complementary action to the whey concentrate for the hydrolysis thereof in order to obtain peptides with an ACE inhibition percentage greater than 70% and an IC | 2012-12-20 |
20120322746 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF OPHTHALMIC DISORDERS - The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant. | 2012-12-20 |
20120322747 | BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS FOR TREATING DRY EYE - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 2012-12-20 |
20120322748 | NOVEL PEPTIDES THAT ENHANCE TIGHT JUNCTION PERMEABILITY - The present invention provides novel peptides that facilitate the opening of mammalian tight junctions. i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent. | 2012-12-20 |
20120322749 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 2012-12-20 |
20120322750 | SOLUBILIZATION AGENT FOR SOLUBILIZING POLYPHENOLS, FLAVONOIDS AND/OR DITERPENOID GLUCOSIDES - Described is a solubilization agent for solubilizing polyphenols, flavonoids and/or diterpenoid glucosides in aqueous liquids, wherein the solubilization agent consists of a mixture of: | 2012-12-20 |
20120322751 | USE OF RHAMNOLIPIDS AS A DRUG OF CHOICE IN THE CASE OF NUCLEAR DISASTERS IN THE TREATMENT OF THE COMBINATION RADIATION INJURIES AND ILLNESSES IN HUMANS AND ANIMALS - This invention is related to the use of one or more rhamnolipids based on structure Formula 1 where the composition of the mixture is useful in the treatment of combination radiation illnesses and regeneration of cells and/or tissues by different application ways of any desirable mentioned rhamnolipids. These rhamnolipid composition mixture are very suitable in the treatment of combination radiation injuries and illnesses and for the regeneration of human and animal cells and tissues after nuclear catastrophes; comprising two or more injuries/illnesses and for cell and tissue regenerations which include radiation damages combined with burns, mechanical injuries, infections of digestive system, infections of lungs, neutropenia, sepsis, atherosclerosis, depression, schizophrenia, atopic eczema and other illnesses in connection with radiation injuries. | 2012-12-20 |
20120322752 | SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL - The present invention provides solid dispersion, comprising: 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol which is a pharmacologically active ingredient; and a saturated polyglycolized glyceride which is a lipid matrix. The solid dispersion of the present invention has effects of increasing dissolution rate of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol. | 2012-12-20 |
20120322753 | PRODUCTION METHOD OF SOLID PREPARATION AND THE SOLID PREPARATIONS PRODUCED BY THE METHOD - The production method prepares a solid preparation by dissolving water-insoluble and/or water indissolvable alkaline active pharmaceutical ingredient in an acidifier-containing acid solution to obtain medicated acid liquid; homogeneously mixing alkalizer, adjuvants and the medicated acid liquid, and carrying out wet granulation. The alkalizer is a reagent to reduce the acidity of the mixture of the alkalizer and the medicated acid liquid relative to the acidity of the medicated acid liquid. The preparation method avoids the problems in mechanical pulverization, such as environmental pollution, great loss and serious security risks. This method is simply operated, has high safety coefficient and is convenient for industrialized production. Also disclosed is the solid preparation produced by the method. The solid preparation produced by the method has better dissolution performance than that produced by prior art, and has better or at least equivalent stability and content uniformity with prior art. | 2012-12-20 |
20120322754 | NOVEL USE FOR SCOPOLIN AND DERIVATIVES THEREOF - The present invention relates to a novel use for the compound of Chemical formula 1 in order to produce drugs or foods for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like, and to a composition for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like which contains the compound of Chemical formula 1 as an active ingredient, and also to a method for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like comprising the administration of the compound of Chemical formula 1 to a mammal in a therapeutically effective dose. According to the present invention, the compound of Chemical formula 1 has been confirmed to suppress the differentiation of adipocytes, to reduce body weight and the amount of visceral fat, to reduce concentrations of cholesterol, triglycerides, free fatty acids and glucose which are associated with fatty liver and diabetes and the like and to reduce the fatty component in liver tissue, to suppress gene expression associated with obesity in visceral fatty tissue, and to increase the amount of expression of UCP1 and UCP3 which are UCP (uncoupling protein) genes involved in thermogenesis. The compound of Chemical formula 1 can be used to advantage in order to prevent or treat obesity, fatty liver, diabetes, metabolic syndrome and the like since, unlike the obesity treating agents based on synthetic drugs currently in use, it is based on a natural substance and hence entails a very low risk of adverse effects and, additionally, it exhibits its pharmacological effects by regulating the expression of genes associated with obesity rather than exhibiting pharmacological effects by acting on enzymes or the nervous system. | 2012-12-20 |
20120322755 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION - This invention provides a cytosine analogue, a method of preparation of a cytosine analogue, a DNA rhethyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation. More precisely, the invention relates to various derivatives of cytosine, as well as methods of preparation of mono- and multi-1,4,5 and 6-substituted cytosines. In general, the solution relates to providing effective modulators of DNA methylation which could be used in prevention and treatment of diseases associated with DNA methylation level disorders. | 2012-12-20 |
20120322756 | METABOLIC IMPRINTING EFFECTS OF STRUCTURED LIPIDS - The invention relates to the use of triglycerides which an enhanced portion of the palmitic acid residues in the sn-2 position for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life. | 2012-12-20 |
20120322757 | Methods for Aloe Processing - A composition and process for generating an anthraquinone rich aloe product from aloe leaves comprising the steps of: removing one or more rind parts from the aloe leaves comprising a top rind, a bottom rind, or both by filleting the aloe leaves on a filleting table into a mucilage layer below the rind parts of the aloe leaves to remove the top rind, the bottom rind, or both from an internal fillet or a gel layer; and separating the internal fillet or the gel layer from the rind parts; removing a mucilage layer attached to the one or more rind parts by scraping, heat-treating the rind parts and the extracted mucilage; and adding one or more preservatives to the heat-treated mucilage after cooling, wherein the extracted and heat-treated mucilage comprises the anthaquinone rich aloe product. | 2012-12-20 |
20120322758 | ANTI-WRINKLE COSMETIC COMPOSITION FOR COMPRISING 3-5 kDa CHITOOLIGOSACCHARIDES - The present invention relates to an anti-wrinkle cosmetic composition comprising chitooligosaccharide as an effective component, more specifically, the cosmetic composition to inhibit collagen degradation induced by UV-A irradiation. | 2012-12-20 |
20120322759 | SEMULOPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS RECEIVING CHEMOTHERAPY - The invention relates to an ultra-low molecular weight heparin with an average molecular weight of 2000 to 3000 Daltons, an anti-FXa activity of about 160 U/mg and an anti-FIIa activity of about 2 U/mg, in particular semuloparin, for use as an antithrombotic agent for the prophylaxis of venous thromboembolism in cancer patients receiving chemotherapy for locally advanced or metastatic solid tumors, more specifically in patients receiving chemotherapy for locally advanced or metastatic pancreatic or lung cancer, or for locally advanced or metastatic solid tumors with a VTE risk score equal to or greater than 3. | 2012-12-20 |
20120322760 | METHODS OF TREATMENT WITH A LOW MOLECULAR WEIGHT HEPARIN COMPOSITION - Methods of identifying and selecting subjects for treatment with a low molecular weight heparin (LMWH) composition are provided. Methods of treatment with the LMWH compositions are also provided. | 2012-12-20 |
20120322761 | HETEROCYCLIC CETP INHIBITORS - Compounds of formula Ia and Ib | 2012-12-20 |
20120322762 | Stable Bortezomib Formulations - Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base. | 2012-12-20 |
20120322763 | Stable Bortezomib Formulations - Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base. | 2012-12-20 |
20120322764 | Acyclic Nucleoside Phosphonate Derivatives and Medical Uses Thereof - The present invention relates to an acyclic nucleoside phosphonate derivative and medical uses thereof. Specifically, the present invention relates to an acyclic nucleoside phosphonate derivative of Formula I having strong potency against viruses, such as hepatitis B virus, and low cytotoxicity, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, wherein R | 2012-12-20 |
20120322765 | PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more inorganic fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of fludioxonil, pencycuron, ametoctradin, chloroneb, chlorothalonil, oxine-copper, cyflufenamid, dichlofluanid, dicloran, diethofencarb, dinocap, dithianon, edifenphos, fenaminosulf, fentin, fluazinam, fluoroimide, flusulfamide, flutianil, fosetyl-Al, hydrargaphen, iprobenfos, metrafenon, milneb, penflufen, phosdiphen, phthalide, prothiocarb, pyrazophos, sedaxane, silthiofam, spiroxamine, tebufloquin, and tolyfluanid. | 2012-12-20 |
20120322766 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS - The present invention relates to the use of compounds, in which the pharmacophores of quinolone and oxazolidinone are chemically linked together through a linker that is stable under physiological conditions, for the treatment of anthrax and other infections. | 2012-12-20 |
20120322767 | FORMULATIONS OF BISPHOSPHONATES AND VITAMIN D SUIUTABLE FOR INTERMITTENT INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION - Compositions for pharmaceutical use are described, comprising bisphosphonates and vitamin D in high concentration, destined to the intramuscular and subcutaneous intermittent administration for treatment of bone and skeletal system diseases, particularly osteoporosis, and sensitive cancers. These formulations are characterized by the use of a lipid and phospholipid emulsion at high concentration, having optimal carrier and solvent power for both the pharmacologically active components. | 2012-12-20 |
20120322768 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING PROTOZOAN INFECTIONS - Provided are compounds, compositions and methods for treating protozoan infections. | 2012-12-20 |
20120322769 | METHODS OF REDUCING VIRULENCE IN BACTERIA - A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein. | 2012-12-20 |
20120322770 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES - This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided. | 2012-12-20 |
20120322771 | GLYCERYL AND GLYCOL ACID COMPOUNDS - Disclosed is a method for reducing the appearance of a fine line or wrinkle on skin comprising topically applying to said fine line or wrinkle a composition comprising a glyceryl di-salicylate compound having the following structure: | 2012-12-20 |
20120322772 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES - The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing. | 2012-12-20 |
20120322773 | MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS - The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a composition includes dihydrolipoic acid as a first reducing agent, an aminosalicylic acid, and a mast cell stabilizer. In another embodiment, the composition further includes a second reducing agent. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. | 2012-12-20 |
20120322774 | CHOCOLATE HAVING CHOLECALCIFEROL AND METHOD FOR FORMING - A method for forming chocolate having cholecalciferol is provided. The method includes mixing cholecalciferol into an oil to produce a cholecalciferol-oil mixture. The temperature of a chocolate base is raised to a melting point, and the cholecalciferol-oil mixture is blended into the chocolate base to form a cholecalciferol-chocolate. | 2012-12-20 |
20120322775 | 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D | 2012-12-20 |
20120322776 | CUTANEOUS COMPOSITION COMPRISING VITAMIN D ANALOGUE AND A MIXTURE OF SOLVENT AND SURFACTANTS - A pharmaceutical composition comprising a vitamin D derivative or analogue as the active ingredient dissolved in a three-component surfactant-solvent mixture is useful in the treatment of dermal disorders or conditions. | 2012-12-20 |
20120322777 | Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology - This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same. | 2012-12-20 |
20120322778 | PHARMACEUTICAL COMPOSITIONS - Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed. | 2012-12-20 |
20120322779 | Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders - The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, neurodegenerative diseases or disorders, such as Alzheimer's disease, Parkinson's Disease, multiple sclerosis, stroke, ALS Pick's disease, prion disease and Huntington's disease. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of the diseases and disorders. | 2012-12-20 |
20120322780 | STEROIDAL COMPOSITIONS - Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein. | 2012-12-20 |
20120322781 | PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES - It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addtion it is provided a method for preparing the pharmaceutical composition. | 2012-12-20 |
20120322782 | VETERINARY COMPOSITIONS - The present invention relates to veterinary compositions in a form of an orally deliverable tablet, and more particularly to a controlled-release composition that provides sufficiently long duration to permit once daily administration. | 2012-12-20 |
20120322783 | TUMESCENT ANTIBIOTIC SOLUTION - Disclosed herein are solutions and kits for tumescent antibiotic delivery. Embodiments of the solution comprise an antibiotic component, an anesthetic component and a vasoconstrictor component. In addition, a method of use is disclosed comprising subcutaneous delivery of the solution. The disclosed solution, kit and method of subcutaneous delivery can be used for a variety of surgical procedures including liposuction, mastectomy and others. The tumescent antibiotic solution can be administered to a patient in situations where establishing IV access is difficult, impossible, or undesirable. A variety of delivery methods appropriate for surgical settings, as well as for use by first responders are likewise disclosed. | 2012-12-20 |
20120322784 | Compounds, pharmaceutical compositions and uses thereof - The present invention relates to compounds of formula I, | 2012-12-20 |
20120322785 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF - The invention provides novel compounds having the general formula: | 2012-12-20 |
20120322786 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): | 2012-12-20 |
20120322787 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - A compound is represented by Structural Formula (I): | 2012-12-20 |
20120322788 | Compouds - The present invention relates to spirocyclic amide derivatives of the formula I, | 2012-12-20 |
20120322789 | ORGANIC COMPOUNDS - The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. | 2012-12-20 |
20120322790 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists - Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. | 2012-12-20 |
20120322791 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS - The present invention provides Pyrazolopyrimidine Compounds of Formula (I): | 2012-12-20 |
20120322792 | Method and Compositions for Treating Cancer and Related Methods - The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy. | 2012-12-20 |
20120322793 | PROTEIN KINASE INHIBITORS - In one aspect, the invention provides compounds of Formula I | 2012-12-20 |
20120322794 | TREATMENT TOOL AND METHOD OF GRADUAL WITHDRAWAL FROM BENZODIAZEPINE DEPENDENCY - A treatment tool and method is disclosed for gradual withdrawal from benzodiazepine dependency while reducing or even minimizing withdrawal symptom intensity. An example method includes reducing emotional stress to maintain current neurotransmitter levels, stabilizing a condition with a pre-taper plan, establishing a maximum daily dosage reduction amount of benzodiazepine, based on historical data to prevent symptom escalation, reducing a current dosage of the benzodiazepine by the maximum daily dosage amount on a daily basis for up to about two weeks, and repeating establishing the maximum daily dosage reduction amount and reducing the current dosage until the daily dosage of benzodiazepine reaches zero. | 2012-12-20 |
20120322795 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 2012-12-20 |
20120322796 | BENZOCYCLOHEPTANE AND BENZOXEPINE DERIVATIVES - The present invention relates to a compound of formula (I) | 2012-12-20 |
20120322797 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS - Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds. | 2012-12-20 |